Gabriel Lopez-Berestein, M.D.
Cancer Nanomedicine and Biology Laboratory
Our laboratory explores the mechanisms of cancer cell survival, tumorigenesis and tumor progression and is focused on identifying signaling pathways regulating proliferation, invasion, drug resistance, apoptosis and autophagy. These studies provide a rational and basis for the development of therapeutic applications using RNA-interference (siRNA and microRNA), oligonucleotides, (antisense), chemotherapeutic agents and small molecules in cancer and a wide variety of other diseases. Nanomedicine functions as a critical bridge that will connect basic science discoveries and clinical applications by enabling the development of highly effective targeted therapies utilizing nanoparticles that capable of delivering therapeutic payloads to disease sites and targeting identified molecular pathways.
Drug Delivery Systems
In addition to our focus on understanding complex biological networks and identifying novel molecular targets in various solid and hematological cancers, we develop novel drug-delivery systems including lipid-based ( ie, nanoliposomes), polymer-based particles (i.e, chitosan, PLA) for delivery therapeutic agents to various solid tumors and hematological cancers . These nanocarriers are designed for the delivery of therapeutic agents to the tumor cells and microenvironment to maximize the therapeutic efficacy of anticancer agents and reduce their side effects if there is any. However, on the developmental component we will further develop a dual assembly nano particle that is capable of sustained release of ncRNAs as we’ll as it is easy amenable to targeting moiety assembly.
Our long-term goal is to development clinically relevant, non-toxic, tumor- targeted nano-therapeutics agents that can be used translated into the clinic to improve the treatment options for the patients therapy and further enhance efficacy of current regimens.